Adjuvax LLC
Birmingham, AL
- UEI
- EGVNJG3GMEL7
- CAGE
- 8RK88
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 622 Renaissance Dr, Birmingham, AL 35226, USA
- Website
- adjuvax.net
- Founded
- 1972
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $3,000,000 |
Contract awards
Similar vendors
About the company
Adjuvax LLC is a small disadvantaged, minority-owned business registered in the System for Award Management (SAM) since October 2020, with a corporate structure as a limited liability company. The organization focuses on biotechnology research and development, specifically in the domain of vaccine and adjuvant technologies. Located in Birmingham, Alabama, Adjuvax LLC appears to be a specialized research firm dedicated to advancing medical technologies through innovative scientific approaches.
The company has secured multiple Small Business Innovation Research (SBIR) contracts from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health. These contracts, totaling $4,200,000, are focused on critical vaccine-related research including adjuvant discovery, production of adjuvant mimics, and optimization of virus-like particle adjuvant formulations. Each contract is set aside for total small business participation and represents Phase I and Phase II SBIR program actions. The most recent and largest contract, awarded in November 2024, is a $3,000,000 firm fixed-price contract supporting SBIR Topic 130, which concentrates on discovering and down-selecting vaccine adjuvants for infectious and immune-mediated diseases. These research efforts are designed to strengthen small businesses' role in meeting federal research and development needs, with all work performed within the United States to advance public health technology development.
Quick answers
Is Adjuvax LLC registered in SAM.gov?
Yes. Adjuvax LLC's SAM.gov registration is active through January 16, 2027.
What is Adjuvax LLC's CAGE code?
Adjuvax LLC's CAGE code is 8RK88, and its Unique Entity ID (UEI) is EGVNJG3GMEL7.
How much has Adjuvax LLC received in federal contracts?
Federal contracts obligated $3,000,000 to Adjuvax LLC in fiscal year 2025.
How does Adjuvax LLC rank among federal contractors?
Adjuvax LLC ranked #62 in PSC AN12 and #92 in NAICS 541714 in FY2025.
What is Adjuvax LLC's most recent federal award?
Adjuvax LLC's most recent federal contract award is Sbir base year - topic 130 adjuvant discovery and down-selection for vaccines against infectious and immune-mediated… (75N93025C00007), from National Institute of Allergy and Infectious Diseases (NIH), on November 1, 2024.
On GovTribe
See Adjuvax LLC's full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors